Overview
Revatis S.A. is a spin-off from the University of Liège dedicated to regenerative medicine and cell therapy. The company has developed patented technology for obtaining multipotent stem cells from muscle micro-biopsies, with applications in veterinary clinical medicine and human medical research.
Key people
In the news
- Yesterday evening in Paris, Revatis supported this nice event. A good opportunity to present our last innovation : the MAPS kit (Mechanical Activated Platelets Secretome). A promising autologous ortho-biologics for pets and horses. #revatis #axovet #orthobiologics #regenerativemedicine #horse #dog #osteoarthritis
- Join us on 4 December in Genk for the Regenerative Medicine Meuse-Rhine Conference (RMMR 2026), bringing together researchers, clinicians, companies and patients. Revatis is an active partner in the FIT Interreg project, contributing to several work packages and supplying muscle-derived stem cells (mdMSCs) to fellow consortium partners. I look forward to seeing you there and discussing progress and perspectives in regenerative medicine! 📍 Thor Central, Genk, Belgium — 4 December 2026, 10:00–17:00 👉 Programme and registration
- Great discussions and valuable new connections at the World Mitochondria Society Congress in Berlin, opening exciting opportunities for future international collaborations and partnerships!
- I really enjoyed attending the World Mitochondria Society Congress 2026 in Berlin and exchanging ideas with researchers sharing a common interest in mitochondria and their role in medicine. I was particularly impressed by the recent advances in mitochondrial transfer between cells, a fascinating field with exciting therapeutic perspectives. It also reinforced my conviction that Revatis’ two patented technology platforms, based on muscle-derived MSCs and their secretome, have much to contribute in this area. A special thanks to
- I really enjoyed attending the World Mitochondria Society Congress 2026 in Berlin and exchanging ideas with researchers sharing a common interest in mitochondria and their role in medicine. I was particularly impressed by the recent advances in mitochondrial transfer between cells, a fascinating field with exciting therapeutic perspectives. It also reinforced my conviction that Revatis’ two patented technology platforms, based on muscle-derived MSCs and their secretome, have much to contribute in this area. A special thanks to
- FDA Authorizes Novel Clinical Trial Exploring Artery-Delivered Stem Cells for Knee Osteoarthritis. (University of Miami) https://lnkd.in/esUD3nAw
- Development of AI based systems to objectively evaluate the efficacy of innovative solutions is crucial for our stemcell products and EVs-rich secretomes
- Proud to participate to this amazing congress. Congratulations to the organizing and scientific committee.
Something wrong or missing? Send an update. Fixed within 24 hours.